Raw Degarelix powder (214766-78-6) video
Raw Degarelix powder (214766-78-6) Description
Raw Degarelix powder, also known as Raw Degarelix powder acetate and FE-200486, a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone. Raw Degarelix powder is specifically indicated for the treatment of advanced prostate cancer.
Raw Degarelix powder is supplied as a powder to be reconstituted with sterile water for subcutaneous administration in the abdomen. The recommended initial dose of the drug is 240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL. The recommended maintenance dose of Raw Degarelix powder is 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL, every 28 days. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
Raw Degarelix powder (214766-78-6) Specifications
|Product Name||Raw Degarelix powder|
|Chemical Name||Raw Degarelix powder acetate; FE-200486; UNII-SX0XJI3A11; SX0XJI3A11; CS-5350; Z-3147; CHEMBL415606; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2;|
|Drug Class||Antineoplastic Agents|
|Monoisotopic Mass||1630.75 g/mol g·mol−1|
|Biological Half-Life||23~61 days|
|Color||White to off-white solid powder|
|Solubility||H2O: ≥ 500 mg/mL|
|Application||Used to treat patients with advanced prostate cancer|
PRECAUTION AND DISCLAIMER:
This Material is Sold For Research Use Only. Terms of Sale Apply. Not for Human Consumption, nor Medical, Veterinary, or Household Uses.